GlycoMimetics, Inc.

GlycoMimetics, Inc. operates as a clinical-stage pharmaceutical company, specializing in the research and development of groundbreaking glycomimetic therapies. Its core mission is to address critical unmet medical requirements arising from various diseases within the United States. A key focus of their pipeline is uproleselan, an E-selectin inhibitor. This drug is being advanced for acute myeloid leukemia (AML), both as a combination therapy with chemotherapy and is currently undergoing a Phase 3 clinical trial for patients experiencing relapsed or refractory forms of AML. Additionally, the company is developing GMI-1359, a compound designed to target both E-selectin and a specific chemokine receptor. This candidate is aimed at treating cancers that affect the bone and bone marrow, encompassing a range of solid tumors. Beyond these lead programs, GlycoMimetics is also progressing other experimental treatments, such as GMI-1687, an E-selectin antagonist intended for the management of vaso-occlusive crises, and a series of galectin-3 antagonists, which are compounds that interact with carbohydrate-binding proteins. In terms of collaborations, GlycoMimetics maintains a cooperative research and development pact with the National Cancer Institute. The company has also entered into a licensing and collaboration deal with Apollomics (Hong Kong) Limited for the global advancement and commercialization of uproleselan and GMI-1687. Founded in 2003, GlycoMimetics, Inc. conducts its operations from its corporate headquarters in Rockville, Maryland.